$NUWE Fundamentally Undervalued
As far as undervalued plays go, Nuwellis, Inc. (NASDAQ: NUWE) could be one of the most undervalued stocks thanks to its cash balance which dwarfs its market cap. Additionally, NUWE has an FDA-cleared device which the company realizes revenues from. With the stock trading near its all-time low, NUWE stock could be one to watch closely in anticipation of a rebound.
NUWE Fundamentals
Cardiology is an extremely important branch of medicine given how essential the heart is. NUWE is a biotech company that specializes in developing cardiology treatments specifically those related to maintaining fluid balance in the heart. Currently, NUWE has a revenue-generating device also known as its Aquadex™ System. This device is approved and cleared for use by the FDA and currently provides NUWE with financial stability via revenue.
With a market cap of only $3.6 million, NUWE could be extremely undervalued especially since the company has $12.1 million in cash, cash equivalents, and marketable securities and has no debt. Considering that NUWE has 1.2 million shares outstanding, the company has nearly $10 in cash per share which makes NUWE stock extremely undervalued at its current valuation. Given that the stock is trading near its all-time low, NUWE could be setting up for a rebound as more investors take notice of this undervalued stock.
NUWE Financials
According to its Q1 report, NUWE’s total assets decreased from $24.6 million to $18.4 million QoQ as a result of its cash balance declining from $17.7 million to $11.5 million. On the other hand, NUWE’s liabilities decreased significantly from $12.3 million to only $4.8 million
NUWE’s revenues dipped slightly YoY from $1.9 million to $1.8 million and as a result, its gross profits dipped slightly as well from $1.1 million to $1 million. Meanwhile, operating costs increased YoY to $6.9 million from $5.5 million which contributed to NUWE’s net loss widening from $4.4 million to $6.4 million.
Technical Analysis
NUWE stock is in a neutral trend and is trading in a sideways channel between its support at 2.82, and its resistance at 3.13. Looking at the indicators, NUWE is trading below the 200, 50, and 21 MAs, however, it is testing both the 50 and 21 MAs as resistance. Meanwhile, the RSI is neutral at 50 and the MACD is neutral.
As for the fundamentals, NUWE could be considered undervalued since it has a cash balance worth more than its entire market cap. In this way, the stock could be poised for a rebound soon as more investors take notice of NUWE. Based on this, bullish investors could wait for the stock to retest its support before entering long positions in anticipation of a bounce in the near term.
NUWE Forecast
Given that NUWE is trading below cash level, the stock could be extremely undervalued at its current $3.6 million market cap since it has nearly $10 in cash per share. With an extremely low float of 1.2 million, NUWE could soar once more investors take notice of the company’s value especially since it already has a revenue-generating FDA-cleared device.
NUWE Fundamentals
Cardiology is an extremely important branch of medicine given how essential the heart is. NUWE is a biotech company that specializes in developing cardiology treatments specifically those related to maintaining fluid balance in the heart. Currently, NUWE has a revenue-generating device also known as its Aquadex™ System. This device is approved and cleared for use by the FDA and currently provides NUWE with financial stability via revenue.
With a market cap of only $3.6 million, NUWE could be extremely undervalued especially since the company has $12.1 million in cash, cash equivalents, and marketable securities and has no debt. Considering that NUWE has 1.2 million shares outstanding, the company has nearly $10 in cash per share which makes NUWE stock extremely undervalued at its current valuation. Given that the stock is trading near its all-time low, NUWE could be setting up for a rebound as more investors take notice of this undervalued stock.
NUWE Financials
According to its Q1 report, NUWE’s total assets decreased from $24.6 million to $18.4 million QoQ as a result of its cash balance declining from $17.7 million to $11.5 million. On the other hand, NUWE’s liabilities decreased significantly from $12.3 million to only $4.8 million
NUWE’s revenues dipped slightly YoY from $1.9 million to $1.8 million and as a result, its gross profits dipped slightly as well from $1.1 million to $1 million. Meanwhile, operating costs increased YoY to $6.9 million from $5.5 million which contributed to NUWE’s net loss widening from $4.4 million to $6.4 million.
Technical Analysis
NUWE stock is in a neutral trend and is trading in a sideways channel between its support at 2.82, and its resistance at 3.13. Looking at the indicators, NUWE is trading below the 200, 50, and 21 MAs, however, it is testing both the 50 and 21 MAs as resistance. Meanwhile, the RSI is neutral at 50 and the MACD is neutral.
As for the fundamentals, NUWE could be considered undervalued since it has a cash balance worth more than its entire market cap. In this way, the stock could be poised for a rebound soon as more investors take notice of NUWE. Based on this, bullish investors could wait for the stock to retest its support before entering long positions in anticipation of a bounce in the near term.
NUWE Forecast
Given that NUWE is trading below cash level, the stock could be extremely undervalued at its current $3.6 million market cap since it has nearly $10 in cash per share. With an extremely low float of 1.2 million, NUWE could soar once more investors take notice of the company’s value especially since it already has a revenue-generating FDA-cleared device.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.